DK2809150T3 - Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner - Google Patents

Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner Download PDF

Info

Publication number
DK2809150T3
DK2809150T3 DK13704329T DK13704329T DK2809150T3 DK 2809150 T3 DK2809150 T3 DK 2809150T3 DK 13704329 T DK13704329 T DK 13704329T DK 13704329 T DK13704329 T DK 13704329T DK 2809150 T3 DK2809150 T3 DK 2809150T3
Authority
DK
Denmark
Prior art keywords
domains
heavy chains
chains containing
mice expressing
humanized mice
Prior art date
Application number
DK13704329T
Other languages
English (en)
Inventor
Lynn Macdonald
Cagan Gurer
Karolina A Meagher
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK2809150T3 publication Critical patent/DK2809150T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Housing For Livestock And Birds (AREA)
DK13704329T 2012-02-01 2013-02-01 Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner DK2809150T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Publications (1)

Publication Number Publication Date
DK2809150T3 true DK2809150T3 (da) 2019-12-09

Family

ID=47714588

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13704329T DK2809150T3 (da) 2012-02-01 2013-02-01 Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner
DK19191081.9T DK3597038T3 (da) 2012-02-01 2013-02-01 Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19191081.9T DK3597038T3 (da) 2012-02-01 2013-02-01 Humaniserede gnavere, der udtrykker tungkæder indeholdende VL-domæner

Country Status (26)

Country Link
US (3) US20130212719A1 (da)
EP (3) EP2809150B1 (da)
JP (6) JP2015505477A (da)
KR (2) KR20140123983A (da)
CN (2) CN106117364B (da)
AU (3) AU2013204758B2 (da)
BR (1) BR112014018843B1 (da)
CA (1) CA2863175A1 (da)
CY (2) CY1122419T1 (da)
DK (2) DK2809150T3 (da)
ES (2) ES2753774T3 (da)
HK (1) HK1202771A1 (da)
HR (2) HRP20192218T1 (da)
HU (2) HUE046744T2 (da)
IL (3) IL233827A0 (da)
LT (2) LT3597038T (da)
ME (1) ME03611B (da)
MX (2) MX2020003491A (da)
NZ (3) NZ719228A (da)
PL (2) PL2809150T3 (da)
PT (2) PT2809150T (da)
RS (2) RS62023B1 (da)
RU (2) RU2770016C2 (da)
SG (3) SG10201913428QA (da)
SI (2) SI2809150T1 (da)
WO (1) WO2013116609A1 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
PL2564695T3 (pl) 2009-07-08 2015-10-30 Kymab Ltd Modele zwierzęce i cząsteczki terapeutyczne
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN113150121A (zh) 2010-08-02 2021-07-23 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
SI3572517T1 (sl) 2011-08-05 2021-09-30 Regeneron Pharmaceuticals, Inc. Humanizirana miš z univerzalno lahko verigo
CA2846322A1 (en) 2011-09-19 2013-03-28 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102038974B1 (ko) 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
HUE046744T2 (hu) * 2012-02-01 2020-03-30 Regeneron Pharma VL doméneket tartalmazó nehézláncokat expresszáló humanizált egér
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
HUE047266T2 (hu) 2012-06-12 2020-04-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
SI2840892T1 (en) 2013-02-20 2018-08-31 Regeneron Pharmaceuticals, Inc. Animals other than humans with modified immunoglobulin heavy chain sequences
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
CA2941514A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA2942697A1 (en) 2014-03-21 2015-09-24 Lynn Macdonald Non-human animals that make single domain binding proteins
EP3271403A1 (en) * 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016161446A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
MX2018014172A (es) 2016-05-20 2019-08-22 Regeneron Pharma Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
WO2018183946A1 (en) * 2017-03-30 2018-10-04 Utah State University Transgenic silkworms expressing spider silk
CN111432635B (zh) * 2017-12-05 2022-10-21 瑞泽恩制药公司 具有经工程改造的免疫球蛋白λ轻链的非人动物以及所述非人动物的用途
CN116874591A (zh) * 2018-03-24 2023-10-13 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗性抗体的经过基因修饰的非人动物、其制造方法和用途
US20190380316A1 (en) * 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
IL301137A (en) 2020-09-11 2023-05-01 Regeneron Pharma Identification and production of antigen-specific antibodies
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
CA2634294A1 (en) * 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
AU2003230741A1 (en) * 2002-03-22 2003-10-13 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
WO2005007696A2 (en) * 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
EP2767161B1 (en) 2004-10-19 2018-02-07 Regeneron Pharmaceuticals, Inc. Method for generating an non-human animal homozygous for a genetic modification
US20060117398A1 (en) * 2004-10-22 2006-06-01 Roland Buelow Suppression of endogenous immunoglobulin expression
EP2505058A1 (en) * 2006-03-31 2012-10-03 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
SG174053A1 (en) * 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
AU2008294074B2 (en) * 2007-08-30 2015-01-22 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
MY163473A (en) * 2007-09-26 2017-09-15 Chugai Pharmaceutical Co Ltd Modified antibody constant region
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
EP2669298A3 (en) * 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
CN105191863B (zh) * 2008-06-27 2020-12-22 莫鲁斯股份有限公司 产生抗体的非人哺乳动物
AU2009287165A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
EP2394159B1 (en) * 2009-02-04 2018-09-26 Molecular Innovations Assays for detecting prorenin, and antibodies used therein
PL2564695T3 (pl) * 2009-07-08 2015-10-30 Kymab Ltd Modele zwierzęce i cząsteczki terapeutyczne
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
WO2011158009A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CN113150121A (zh) * 2010-08-02 2021-07-23 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
RS59413B2 (sr) * 2011-02-25 2023-06-30 Regeneron Pharma Adam6 miševi
SI3572517T1 (sl) * 2011-08-05 2021-09-30 Regeneron Pharmaceuticals, Inc. Humanizirana miš z univerzalno lahko verigo
KR102038974B1 (ko) * 2011-12-20 2019-10-31 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
HUE046744T2 (hu) * 2012-02-01 2020-03-30 Regeneron Pharma VL doméneket tartalmazó nehézláncokat expresszáló humanizált egér
HUE047266T2 (hu) * 2012-06-12 2020-04-28 Regeneron Pharma Korlátozott immunglobulin nehézlánc lókuszokkal rendelkezõ, humanizált, nem humán élõlények
CN109996441B (zh) * 2016-11-04 2022-02-08 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物

Also Published As

Publication number Publication date
IL261280A (en) 2018-10-31
JP2015505477A (ja) 2015-02-23
SI3597038T1 (sl) 2021-07-30
CN104202971B (zh) 2016-07-06
JP2023168590A (ja) 2023-11-24
HUE046744T2 (hu) 2020-03-30
CN106117364A (zh) 2016-11-16
KR20190006029A (ko) 2019-01-16
MX2020003491A (es) 2022-10-25
AU2015246154A1 (en) 2015-11-12
ME03611B (me) 2020-07-20
WO2013116609A1 (en) 2013-08-08
AU2015246154B2 (en) 2017-11-23
HUE055610T2 (hu) 2021-12-28
JP7187615B2 (ja) 2022-12-12
IL268675B (en) 2020-11-30
PT2809150T (pt) 2019-12-09
JP2023014242A (ja) 2023-01-26
DK3597038T3 (da) 2021-06-28
IL261280B (en) 2019-08-29
JP6698718B2 (ja) 2020-05-27
LT3597038T (lt) 2021-05-25
LT2809150T (lt) 2019-10-25
AU2013204758A1 (en) 2013-08-15
RU2018122695A (ru) 2019-03-06
HRP20210987T1 (hr) 2021-09-17
ES2753774T3 (es) 2020-04-14
PL2809150T3 (pl) 2020-04-30
EP3597038B1 (en) 2021-04-21
RU2770016C2 (ru) 2022-04-14
JP2018075041A (ja) 2018-05-17
HK1202771A1 (en) 2015-10-09
PL3597038T3 (pl) 2021-11-08
US20210368751A1 (en) 2021-12-02
EP2809150B1 (en) 2019-09-18
AU2017251848B2 (en) 2020-02-20
BR112014018843A2 (pt) 2017-07-04
RU2664185C2 (ru) 2018-08-15
JP2019170395A (ja) 2019-10-10
CY1124361T1 (el) 2022-07-22
ES2870703T3 (es) 2021-10-27
NZ627977A (en) 2016-06-24
SI2809150T1 (sl) 2019-11-29
CY1122419T1 (el) 2021-01-27
CA2863175A1 (en) 2013-08-08
SG11201404477YA (en) 2014-08-28
NZ719228A (en) 2022-08-26
BR112014018843B1 (pt) 2024-02-20
US20130212719A1 (en) 2013-08-15
NZ734504A (en) 2022-10-28
RU2018122695A3 (da) 2021-10-06
CN104202971A (zh) 2014-12-10
EP2809150A1 (en) 2014-12-10
JP2021137030A (ja) 2021-09-16
CN106117364B (zh) 2021-08-31
HRP20192218T1 (hr) 2020-03-06
RS59699B1 (sr) 2020-01-31
SG10201606256TA (en) 2016-09-29
RS62023B1 (sr) 2021-07-30
PT3597038T (pt) 2021-05-10
AU2017251848A1 (en) 2017-11-16
RU2014133653A (ru) 2016-03-20
US20170094955A1 (en) 2017-04-06
KR20140123983A (ko) 2014-10-23
EP3912465A1 (en) 2021-11-24
IL268675A (en) 2019-10-31
SG10201913428QA (en) 2020-03-30
AU2013204758B2 (en) 2015-07-23
IL233827A0 (en) 2014-09-30
EP3597038A1 (en) 2020-01-22
BR112014018843A8 (pt) 2019-01-29
JP6942757B2 (ja) 2021-09-29
MX2019002517A (es) 2019-06-17

Similar Documents

Publication Publication Date Title
DK2809150T3 (da) Humaniserede mus, der udtrykker tungkæder indeholdende VL-domæner
DK2958938T3 (da) Mus, der eksprimerer humaniserede T-celle-co-receptorer
DK2934584T3 (da) Anti-gdf15-antistoffer
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
DK2850101T3 (da) Anti-FcRn-antistoffer
BR302013000789S1 (pt) Configuração aplicada em mecanismo de entrada.
BR302013000038S1 (pt) Configuração aplicada em recipiente
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
BR302012005545S1 (pt) Configuração aplicada em recipiente.
BR302012005547S1 (pt) Configuração aplicada em recipiente.
BR302012005542S1 (pt) Configuração aplicada em recipiente.
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
BR302012005494S1 (pt) Configuracao aplicada em recipiente
BR302012005543S1 (pt) Configuração aplicada em recipiente.
DK2895514T3 (da) Hydrotermisk modificeret stivelse
BR302013002770S1 (pt) Configuração aplicada em recipiente.
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
BR302012005544S1 (pt) Configuração aplicada em recipiente.
BR302012005548S1 (pt) Configuração aplicada em recipiente.
DK2809381T3 (da) Injektionsindretninger
DK2828292T3 (da) Jcv-neutraliserende antistoffer
BR302012005495S1 (pt) Configuracao aplicada em recipiente
BR302012004876S1 (pt) Configuracao aplicada em embalagem.
DK2935330T3 (da) Anti-notch3-antistoffer
DK3521315T3 (da) Anti-transglutaminase-2-antistoffer